FindTrial
Sign In

Comparison of Lercanidipine with Felodipine in Essential Hypertension

Comparison of Lercanidipine with Felodipine in Essential Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000650
Enrollment
Unknown
Registered
2005-09-09
Start date
2001-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart and Blood Vessel Diseases

Interventions

Two groups:Lercanidipine 16 weeks versus Felodipine

Sponsors

Schwarz Pharma (HK) Ltd
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with mild to moderate essential hypertension

Exclusion criteria

Exclusion criteria: Patients with uncontrolled hypertension or diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Changes in ambulatory blood pressure;—

Secondary

MeasureTime frame
renal function, glucose and lipid profile, markers of oxidative stress;—

Countries

China

Contacts

Public ContactBrian Tomlinson
www.na@163.com+852 26323139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026